Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1
3(50.0%)
Phase 2
3(50.0%)
6Total
Phase 1(3)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03396497Phase 1Unknown

Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer

Role: lead

NCT02929862Phase 1Completed

Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer

Role: lead

NCT02872285Phase 2Completed

An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis

Role: lead

NCT02762500Phase 2Completed

An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis

Role: lead

NCT02764229Phase 2Terminated

Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis

Role: lead

NCT02818543Phase 1Completed

Safety and Pharmacokinetic Study of LYC-30937 in Subjects With Active Ulcerative Colitis

Role: lead

All 6 trials loaded